skip to Main Content

Ending Viral Disease

We’re developing a broad-spectrum antiviral to treat a range of viral diseases.
Our vision is an end to the suffering of hundreds of millions of humans and animals.

Our Work

There’s never been a greater need for an effective antiviral. We have developed a new broad-spectrum antiviral compound that has shown the potential to be effective against a wide range of clinical and priority viruses. We call our compound ‘VTose®’.

Latest News

Kimer Med was awarded a 2021-22 Project Grant from Callaghan Innovation, the New Zealand government’s innovation agency. This funding provides a boost to our ongoing R&D work by reimbursing NZD$150,000 of our eligible expenses over the next two years.

Support Us

Our goal is to end viral disease, and we need your help to achieve it! You can support this critical research by donating and also by spreading the word about what we are doing. Your support is welcome and very much appreciated – and every dollar counts.

We're working on a new broad-spectrum antiviral drug.

Kimer Med is a post-seed biotech start-up, located in Nelson, New Zealand. We’re optimising a new, broad-spectrum antiviral drug. The compound, which we call VTose, is a derivative of DRACO, which was tested and found effective in vitro against 15 different viruses in 11 tissue types, and against Influenza H1N1 in mice.

Antivirals are a vital tool to deal with viral disease

Historically and currently, the harm to human life caused by pathogenic viruses is on an enormous scale! In years gone by, viruses such as smallpox killed hundreds of millions, perhaps over 300 million as late as the 20th century. The polio virus paralysed over 15,000 people annually. The 1918 flu pandemic killed upwards of 100 million.

Read more about our efforts to address this age-old problem.

Read the Latest News and Articles from Kimer Med

Join the conversation

You can contribute to our efforts to end viral disease. Talk with our co-founders, other professionals and interested parties about the development of our new broad-spectrum antiviral drug.

Back To Top